Literature DB >> 26405290

The changing face of a rare disease: lymphangioleiomyomatosis.

Sergio Harari1, Olga Torre2, Roberto Cassandro3, Joel Moss4.   

Abstract

Lymphangioleiomyomatosis is a rare disease characterised by cystic destruction of the lung, lymphatic abnormalities and abdominal tumours. It affects almost exclusively females and can occur sporadically or in patients with tuberous sclerosis complex. In the past decade remarkable progress has been made in understanding of the pathogenesis of this disease leading to a new therapeutic approach. This review summarises recent advances regarding pathogenic mechanisms and clinical manifestations, and highlights the current and the most promising future therapeutic strategies.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26405290     DOI: 10.1183/13993003.00412-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

Review 1.  Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review.

Authors:  Sakda Sathirareuangchai; David Shimizu; Koah Robin Vierkoetter
Journal:  Hawaii J Health Soc Welf       Date:  2020-07-01

2.  Clinical CT underestimation of the percentage volume occupied by cysts in patients with lymphangioleiomyomatosis.

Authors:  Thomas C Larsen; Amir M Hasani; Shirley F Rollison; Tania R Machado; Amanda M Jones; Patricia Julien-Williams; Marcus Y Chen; Joel Moss; Han Wen
Journal:  Clin Imaging       Date:  2019-11-27       Impact factor: 1.605

3.  Pulmonary Langerhans Cell Histiocytosis and Lymphangioleiomyomatosis Have Circulating Cells With Loss of Heterozygosity of the TSC2 Gene.

Authors:  Davide Elia; Olga Torre; Chiara Vasco; Jens Geginat; Sergio Abrignani; Elisabetta Bulgheroni; Elena Carelli; Roberto Cassandro; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Joel Moss; Sergio Harari
Journal:  Chest       Date:  2022-02-26       Impact factor: 10.262

4.  Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.

Authors:  Sergio Harari; Davide Elia; Olga Torre; Elisabetta Bulgheroni; Elena Provasi; Joel Moss
Journal:  Chest       Date:  2016-08       Impact factor: 9.410

5.  Risk factors for right ventricular dysfunction in patients with lymphangioleiomyomatosis.

Authors:  Wei Hua; Wenbo Yang; Jianing Gu; Jialiang Wu; Wei Wang; Yanpu Liu; Hong Zhu; Min Zhou; Jieming Qu; Yuehua Fang
Journal:  Int J Cardiovasc Imaging       Date:  2020-09-14       Impact factor: 2.357

6.  Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis.

Authors:  Brianna P Matthew; Amir M Hasani; Yun-Ching Chen; Mehdi Pirooznia; Mario Stylianou; Shirley F Rollison; Tania R Machado; Nora M Quade; Amanda M Jones; Patricia Julien-Williams; Angelo Taveira-DaSilva; Marcus Y Chen; Joel Moss; Han Wen
Journal:  Chest       Date:  2021-02-05       Impact factor: 9.410

7.  Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort.

Authors:  Vissagan Gopalakrishnan; Amanda M Jones; Patricia Julien-Williams; Tania Machado; Robert L Danner; Jeffrey J Swigris; Robert Paine; Jay N Lozier; Joel Moss
Journal:  ERJ Open Res       Date:  2018-03-20

Review 8.  Lung Diseases Unique to Women.

Authors:  Rachel N Criner; Abdullah Al-Abcha; Allison A Lambert; MeiLan K Han
Journal:  Clin Chest Med       Date:  2021-09       Impact factor: 4.967

9.  Lung disease recalling paraseptal emphysema in a patient with Goltz syndrome.

Authors:  Rosaria Cortese; Salvatore Savasta; Silvia Di Stasi; Tiziana Boggini; Chiara Trabatti; Roberto Dore; Giulia Maria Stella
Journal:  Multidiscip Respir Med       Date:  2016-09-13

Review 10.  Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

Authors:  Samy L Habib; Noor Y Al-Obaidi; Maciej Nowacki; Katarzyna Pietkun; Barbara Zegarska; Tomasz Kloskowski; Wojciech Zegarski; Tomasz Drewa; Edward A Medina; Zhenze Zhao; Sitai Liang
Journal:  J Cancer       Date:  2016-07-21       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.